ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
House Subcommittee Advances Prior Authorization Legislation
The House of Representatives Energy and Commerce Subcommittee on Health has advanced…
Lawmakers Seek to Halt Medicare’s AI-Assisted Prior Authorization Model
The House of Representatives Appropriations Committee has approved legislation that, if passed,…
ASNC Delegates Help American Medical Association Shape AI and Prior Auth Policies
At last week’s American Medical Association (AMA) House of Delegates meeting, policies…

